A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Cancer
Both
Cancer
Trial Information
A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma
Inclusion Criteria:
- >18 years old
- histologically confirmed solid tumor malignancy
- refractory to available therapy or for which no therapy is available
- adequate organ function
Exclusion Criteria:
- CNS malignancy
- significant GI disease
- at risk for prolonged QT interval
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
adverse events and other safety assessments
Outcome Time Frame:
continuous
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
B1311001
NCT ID:
NCT00506805
Start Date:
June 2007
Completion Date:
March 2010
Related Keywords:
- Cancer
- solid tumor malignancy; Hsp90
- Neoplasms
- Lymphoma, Non-Hodgkin
Name | Location |
|---|---|
| Pfizer Investigational Site | Flagstaff, Arizona 86001 |
| Pfizer Investigational Site | Bristol, Tennessee 37620 |
